Holen Sie sich die Stockscreener-App
25.03
2.80%
-0.72
Schlusskurs vom Vortag:
$25.75
Offen:
$25.67
24-Stunden-Volumen:
631.86K
Relative Volume:
0.48
Marktkapitalisierung:
$1.80B
Einnahmen:
$81.26M
Nettoeinkommen (Verlust:
$-102.66M
KGV:
-18.30
EPS:
-1.3678
Netto-Cashflow:
$-77.62M
1W Leistung:
-2.95%
1M Leistung:
-4.61%
6M Leistung:
-7.98%
1J Leistung:
+34.93%
1-Tages-Spanne:
$24.94
$25.86
1-Wochen-Bereich:
$24.60
$26.21
52-Wochen-Spanne:
$16.00
$31.34
Zymeworks Bc Inc Stock (ZYME) Company Profile
Firmenname
Zymeworks Bc Inc
Sektor
Branche
Telefon
302-274-8744
Adresse
108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
Compare ZYME vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Bc Inc
|
25.03 | 1.80B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zymeworks Bc Inc Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-29 | Eingeleitet | TD Cowen | Buy |
| 2026-09-17 | Eingeleitet | Wolfe Research | Outperform |
| 2026-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2026-06-09 | Fortgesetzt | Truist | Buy |
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-10-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Bc Inc Aktie (ZYME) Neueste Nachrichten
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results - GlobeNewswire Inc.
Zymeworks EVP Schayowitz sells $357,557 in shares By Investing.com - Investing.com Nigeria
Diluted shares outstanding of Zymeworks Inc. – HAN:ZA8 - TradingView
Form 4 Zymeworks Inc For: 12 October By Investing.com - Investing.com Nigeria
Zymeworks EVP Adam Schayowitz sells $357,557 in shares - Investing.com
Zymeworks EVP Adam Schayowitz sells $357,557 in ZYME stock for taxes - Investing.com
Zymeworks EVP, head of R&D Adam Schayowitz sells $357,557 in stock. - Investing.com
Form 4 Zymeworks Inc For: 9 October By Investing.com - Investing.com South Africa
Zymeworks (NASDAQ:ZYME) Stock: Insider Adam Schayowitz Sells 13,832 Shares - MarketBeat
A mandatory sale covers taxes: Zymeworks (ZYME) R&D head sells 13,832 shares at $25.85. - Stock Titan
Form 144 Zymeworks Inc. For: 9 October By Investing.com - Investing.com Nigeria
Officer Adam Schayowitz proposes selling 13,832 shares of Zymeworks (Nasdaq: ZYME). - Stock Titan
Jefferies keeps Buy on Zymeworks stock at USD 50 target - AD HOC NEWS
Zymeworks stock fell 2.14 percent as 2026 guidance reset - AD HOC NEWS
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook - TradingView
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook - Yahoo Finance
EBIT per share of Zymeworks Inc. – HAN:ZA8 - TradingView
CapEx per share of Zymeworks Inc. – HAN:ZA8 - TradingView
Taxes of Zymeworks Inc. – HAN:ZA8 - TradingView
Zymeworks stock coverage reinstated at Buy by TD Cowen on acquisition - Investing.com Nigeria
Citigroup keeps 'Buy' on Zymeworks after acquis... - Pluang
Zymeworks stock coverage reinstated at Buy by TD Cowen on acquisition - Investing.com Canada
Dilution adjustment of Zymeworks Inc. – HAN:ZA8 - TradingView
Zymeworks Inc. (ZYME) stock price, news, quote and history - Yahoo Finance UK
Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Eyes Growth in COPD Market - GuruFocus
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - TradingView
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - Benzinga
Zymeworks Completes Theravance Acquisition Deal - grafa.com
Zymeworks Inc. Updates Earnings Guidance for the Year 2026 - marketscreener.com
Zymeworks Inc. Updates Earnings Guidance for the Year 2026 - marketscreener.com
Zymeworks Inc. (ZYME) Theravance Biopharma, Inc.M&A CallSlideshow (NASDAQ:ZYME) 2026-09-28 - Seeking Alpha
Zymeworks Inc. and Theravance Biopharma, Inc. Acquisition Call Transcript - GuruFocus
Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Int - GuruFocus
Zymeworks Inc Expects Total Revenue, Including Collaboration Revenue From Yupelri, For 2026 To Be Between $278 Million And $292 Million - TradingView
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition - GlobeNewswire Inc.
Zymeworks Announces Updated 2026 Financial Guidance and - GlobeNewswire
Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition - Yahoo Finance
Vancouver biotech Zymeworks closes US$929M Theravance deal - Business in Vancouver
A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan
Zymeworks Completes Acquisition of Theravance Biopharma - GlobeNewswire
Zymeworks Completes Acquisition of Theravance Biopharma - Yahoo Finance
Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME) - Seeking Alpha
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME - MarketBeat
Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME - MarketBeat
Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME - MarketBeat
Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME - MarketBeat
JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00 - MarketBeat
Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat
Finanzdaten der Zymeworks Bc Inc-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zymeworks Bc Inc-Aktie (ZYME) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Adam Schayowitz | officer |
Oct 09 '26 |
Proposed Sale |
25.26 |
13,832 |
349,396 |
0 |
| Schayowitz Adam | EVP, Head of R&D |
Oct 09 '26 |
Sale |
25.85 |
13,832 |
357,557 |
23,205 |
| Jeffrey T L Smith | Former Officer |
Mar 06 '26 |
Proposed Sale |
24.80 |
247,333 |
6,133,858 |
0 |
| Leone D Patterson | Former officer |
Feb 17 '26 |
Proposed Sale |
22.60 |
31,641 |
715,087 |
0 |
| Leone D Patterson | Former officer |
Feb 13 '26 |
Proposed Sale |
23.17 |
128,548 |
2,978,457 |
0 |
| Kenneth Galbraith | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
30,424 |
704,924 |
0 |
| Paul Andrew Moore | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
9,560 |
221,505 |
0 |
| Jeffrey T L Smith | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
9,310 |
215,713 |
0 |
| Mark Hollywood | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
6,120 |
141,800 |
0 |
| Hollywood Mark | EVP & Chief Operating Officer |
Jan 12 '26 |
Option Exercise |
0.00 |
17,666 |
0 |
139,033 |
3.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):